# Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy

> **NCT05523869** · PHASE2 · RECRUITING · sponsor: **Unity Health Toronto** · enrollment: 50 (estimated)

## Conditions studied

- Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment

## Interventions

- **DRUG:** Intravitreal topotecan
- **PROCEDURE:** Pars plana vitrectomy with or without scleral buckle

## Key facts

- **NCT ID:** NCT05523869
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-23
- **Primary completion:** 2026-02
- **Final completion:** 2026-02
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05523869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05523869, "Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05523869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*